Xolair is the first in a new generation of drugs for severe, difficult-to-control allergic asthma, where patients have an oversensitive immune system. It is a steroid free medication which is given by injection every two or four weeks.
Xolair has been shown to reduce emergency admissions to hospital, improve lung function and reduce asthma symptoms. It is suitable for people over the age of 12 years who have moderate to severe persistent asthma symptoms despite taking regular inhaled corticosteroid treatment.
There are 520,000 people with asthma in the UK for whom existing treatments do not work, and Xolair can provide a solution for around 6,000 of them.
Xolair is only available through respiratory clinics within the hospital following an assessment which will include a blood test to see if it will be suitable. People with persistent asthma symptoms and who have had two or more hospital admissions for asthma over a year may be considered for Xolair.
Follow us on Twitter
Find us on Facebook